American Heart Journal
Volume 158, Issue 5 , Pages 785-791, November 2009

Does intensity of rate control influence outcome in persistent atrial fibrillation?

Data of the RACE study

  • Hessel F. Groenveld, MD

      Affiliations

    • Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands
  • ,
  • Harry J.G.M. Crijns, MD, PhD

      Affiliations

    • Department of Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands
  • ,
  • Michiel Rienstra, MD, PhD

      Affiliations

    • Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands
  • ,
  • Maarten P. Van den Berg, MD, PhD

      Affiliations

    • Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands
  • ,
  • Dirk J. Van Veldhuisen, MD, PhD, FACC

      Affiliations

    • Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands
  • ,
  • Isabelle C. Van Gelder, MD, PhD

      Affiliations

    • Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands
    • Interuniversity Cardiology Institute Netherlands, Utrecht, The Netherlands
    • Corresponding Author InformationReprint requests: Isabelle C. Van Gelder, MD, PhD, Department of Cardiology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.
  • ,
  • for the RACE investigators

      Affiliations

    • Participants in the RACE for Persistent Atrial Fibrillation Study are listed elsewhere (2).

Received 6 May 2009; accepted 13 September 2009.

Background

Large trials have demonstrated that rate control is an acceptable alternative for rhythm control. However, optimal heart rate during atrial fibrillation (AF) remains unknown. Aim of this analysis was to compare outcome between rate control ≥80 and <80 beat/min in patients with persistent atrial fibrillation.

Methods

In the RAte Control versus Electrical cardioversion for persistent atrial fibrillation study, 522 patients were included, and 256 were randomized to rate control. This post hoc analysis included patients randomized to rate control. Patients were divided according to their mean resting heart rate during follow-up, <80 beat/min (n = 75) or ≥80 beat/min (n = 139). The end point, a composite of cardiovascular mortality, heart failure, thromboembolic complications, bleeding, pacemaker implantation, and severe drug side effects, was compared between both groups.

Results

During follow-up (2.3 ± 0.6 years), a significant difference between both groups in heart rate was observed (72 ± 5 vs 90 ± 8 beat/min; P < .001). Rate control drugs were not significantly different between both groups. New York Heart Association class and fractional shortening remained unchanged in both groups. There were 17 (23%) end points in the low heart rate group and 24 (17%) in the higher heart rate group (absolute difference, 5.4 [−7.3 to 8.2]; P = ns). Independent predictors for the primary end point were coronary artery disease, digoxin use, and interrupted anticoagulation, not high heart rate. Quality of life was comparable in both groups during follow-up.

Conclusions

In patients treated with a rate control strategy, no differences were observed in terms of cardiovascular morbidity, mortality, and quality of life between the observed differences in level of rate control throughout follow-up.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0002-8703(09)00724-8

doi:10.1016/j.ahj.2009.09.007

American Heart Journal
Volume 158, Issue 5 , Pages 785-791, November 2009